Example: Heart Attack

Search clinical trials for: Fulvestrant

Total 311 results

NCT04556773

Not yet recruiting

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04557449

Not yet recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Conditions: Liposarcoma; CRC; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung; Solid Tumors
NCT04544189

Not yet recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Conditions: Breast Neoplasms
NCT04526028

Recruiting

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Conditions: Breast Cancer; Fulvestrant; Palbociclib
NCT04524000

Not yet recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Conditions: Advanced Breast Cancer
NCT04524728

Completed

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Conditions: Breast; Neoplasm Malignant; Female
NCT04504331

Not yet recruiting

Phase 1B Infigratinib +/-Tamoxifen or Fulvestrant&Palbociclib in Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-)/Fibroblast Growth Factor Receptors (FGFR) Altered BreastCancer

Conditions: Breast Cancer; HER2-negative Breast Cancer; ER Positive Breast Cancer; ER-Negative Breast Cancer
NCT04498481

Completed

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Conditions: Breast Cancer
NCT04498520

Not yet recruiting

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Conditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Endometrioid Adenocarcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Breast Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8
NCT04483505

Not yet recruiting

Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

Conditions: Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast
NCT04473040

Available

Managed Access Program (MAP)* to Provide Access to Alpelisib, in Combination With Fulvestrant (ET) in Postmenopausal Women With Advanced Breast Cancer

Conditions: Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer With a PIK3CA Mutation
NCT04460911

Active, not recruiting

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Conditions: Breast Cancer
NCT04460430

Not yet recruiting

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Conditions: Breast Cancer
NCT04355520

Not yet recruiting

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Conditions: HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
NCT04352777

Not yet recruiting

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Conditions: Metastatic Breast Cancer; Locally Advanced Breast Cancer; Hormone Receptor Positive Tumor
NCT04337658

Not yet recruiting

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Conditions: HER2-positive Breast Cancer
NCT04334330

Not yet recruiting

Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Conditions: Breast Cancer; Brain Metastases
NCT04318223

Recruiting

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Conditions: Metastatic Breast Cancer; Locally Advanced Breast Cancer
NCT04316169

Not yet recruiting

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Conditions: Solid Tumor; Advanced Breast Cancer
NCT04305236

Not yet recruiting

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Conditions: Breast Neoplasm; Hormone Receptor Positive Breast Carcinoma
NCT04305496

Recruiting

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
NCT04300790

Not yet recruiting

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Conditions: Breast Cancer
NCT04289974

Recruiting

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Conditions: Breast Cancer
NCT04282031

Recruiting

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Conditions: Advanced Solid Tumor; Breast Neoplasms
NCT04263298

Recruiting

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04258163

Completed

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Conditions: Metastatic Breast Cancer
NCT04256941

Recruiting

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8
NCT04247126

Recruiting

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Conditions: Advanced Solid Tumor; Breast Cancer
NCT04224272

Recruiting

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Conditions: HER2+/HR+ Breast Cancer
NCT04227327

Recruiting

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Conditions: Advanced Breast Cancer
NCT04214288

Recruiting

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Conditions: Advanced ER-Positive HER2-Negative Breast Cancer
NCT04215003

Not yet recruiting

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Conditions: Breast Cancer
NCT04191499

Recruiting

A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Cancer
NCT04158362

Recruiting

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

Conditions: Cancer Metastatic
NCT04060862

Recruiting

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Conditions: Breast Cancer
NCT04059484

Recruiting

Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Conditions: Breast Cancer Metastatic
NCT04053322

Recruiting

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Conditions: ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
NCT04034589

Recruiting

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04033172

Recruiting

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Conditions: Breast Cancer; HER2-positive Breast Cancer
NCT04031885

Suspended

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04024436

Recruiting

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer; FGFR2 Amplification
NCT03959891

Recruiting

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Conditions: Breast Cancer
NCT03939897

Recruiting

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer - Dose-Finding Study

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma
NCT03926936

Recruiting

FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study

Conditions: Endometrial Stromal Sarcoma; Adenosarcoma of Uterus; Leiomyosarcoma Uterus; Endometrial Cancer; Sex Cord Stromal Tumor; Serous Ovarian Tumor
NCT03927456

Not yet recruiting

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Conditions: Advanced Breast Cancer
NCT03925233

Enrolling by invitation

Breast Cancer Treatment Based on Organ-like Culture

Conditions: Breast Cancer Organoids
NCT03854903

Recruiting

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Conditions: Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer
NCT03820830

Recruiting

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Conditions: Breast Cancer Recurrent
NCT03809988

Recruiting

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Conditions: Breast Cancer; Advanced Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
NCT03803761

Not yet recruiting

Study of a New Drug Combination, Copanlisib and Fulvestrant, in Postmenopausal Women With Advanced Breast Cancer

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma Metastatic in the Brain; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Postmenopausal; Prognostic Stage IV Breast Cancer AJCC v8

COOKIE SETTINGS

Search clinical trials for: Fulvestrant